Sitagliptin and Cancer

The link between sitagliptin and cancer is a serious concern for many type 2 diabetics. If you or a family member took sitagliptin and pancreatic cancer developed, talk to an experienced pharmaceutical lawyer about your potential claim against the drugmaker.

What is Sitagliptin?

Sitagliptin is the first in a new class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. Marketed as Januvia, Janumet, Janumet XR, and Juvisync, sitagliptin is an oral diabetes drug in the incretin mimetic class currently under scrutiny by the U.S. Food and Drug Administration (FDA).

Developed by Merck and prescribed to help control blood sugar levels in type 2 diabetics, the drug works as an incretin enhancer, prohibiting the degradation of incretin hormones and prolonging their action. Sitagliptin first hit the U.S. market in 2006 under the brand name Januvia.

Sitagliptin and Cancer: Studies Show Increased Risk

Multiple studies since 2006 have linked DPP-4 inhibitors to melanoma, thyroid, colon, prostate and pancreatic cancer. New York Times Best Selling Author, Dr. Joseph Mercola, outlines those studies in DPP-4 Inhibitors — Another Disastrous Diabetes Drug. In the article, Dr. Mercola explains the concern about a drug that inhibits DPP-4, one of the body’s natural cancer suppressing mechanisms. Dr. Mercola also points to a connection between big pharmaceutical companies funding research that purportedly debunked the link between DPP-4 inhibitors and GLP-1 agonist drugs (such as Byetta) and an increased relative risk of developing cancer.

FDA Investigates Sitagliptin Pancreatic Cancer Risk

For years some researchers have believed there is a sitagliptin pancreatic cancer risk. In 2009 the FDA warned about 88 post-marketing cases of acute pancreatitis in patients taking sitagliptin. Risk factors for acute pancreatitis can also be risk factors for pancreatic cancer.

New findings by a group of academic researchers suggesting an association between incretin mimetics, including sitagliptin, and pre-cancerous cellular changes prompted the FDA to investigate the researcher’s findings further. The FDA announced its investigation in mid-March 2013.

Sitagliptin Pancreatic Cancer Lawsuit

If you or a family member were diagnosed with cancer while or after taking Januvia, Janumet, Janumet XR, or Juvisync, and you are now considering a sitagliptin pancreatic cancer lawsuit, you need a law firm not only experienced in handling injury and wrongful death claims against a large pharmaceutical company, but also with the resources to do so successfully.

One of the country’s most successful pharmaceutical injury firms, Watts Guerra LLP, is currently handling the largest incretins pancreatic cancer injury and wrongful death docket in the U.S. Contact the firm now for a free case review.

Disclaimer: The images on this page of the Januvia packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Merck & Co., Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.

Ryan L. Thompson

Ryan L. Thompson Ryan L. Thompson leads the firm's pharmaceutical and medical device litigation department. He serves as the firm's lead counsel for Actos, NuvaRing, DePuy Hips, Transvaginal Mesh, and other torts. Additionally, Ryan was appointed to serve as Co-Lead counsel nationally in the Incretin-Based Therapies MDL by US District Judge Anthony Battaglia for plaintiff's claiming injuries related to Byetta, Januvia, Janumet, and Victoza.
Contact us using our online form, or call us toll-free at 1(800)796-9605.